Alpha Tau Medical Ltd.

Alpha DaRT Ltd. is a clinical-stage oncology therapeutics company that develops localized radiation therapy for solid tumors using alpha particles. The company's proprietary Alpha DaRT technology is designed to utilize the therapeutic properties of alpha particles while addressing their limited range. Alpha DaRT Ltd. is developing this technology for various applications, including refractory or unresectable localized tumors, tumor types with high unmet needs like pancreatic adenocarcinoma or glioblastoma multiforme, and metastatic tumors in combination with systemic therapies. The company has evaluated the Alpha DaRT technology's feasibility, safety, and efficacy for treating superficial lesions, such as tumors of the skin, head, or neck, in multiple clinical trials globally. In August 2020, Alpha DaRT Ltd. received marketing approval in Israel for treating squamous cell carcinoma (SCC) of the skin or oral cavity using Alpha DaRT. The U.S. Food and Drug Administration (FDA) granted Alpha DaRT Breakthrough Device Designation in June 2021 for treating patients with SCC of the skin or oral cavity without curative standard of care. In October 2021, the FDA granted a second Breakthrough Device Designation for Alpha DaRT in treating recurrent Glioblastoma Multiforme (GBM), either as an adjunct to standard medical therapies or as a standalone therapy after standard medical therapies have been exhausted. In the second half of 2021, ten patients were treated in the U.S. in a multi-center pilot feasibility trial conducted at Memorial Sloan Kettering Cancer Center and four other U.S. sites.